Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GRM8 | O00222 | 2/20 | 0.35 |
| ▸ | GRM6 | O15303 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954390 | 1.00 | NSD2 (0.38) | NSD2GRM4CYP1A2CYP2C19ALOX15 | |
| SCHEMBL29955088 | 1.00 | NSD2 (0.38) | NSD2GRM4CYP1A2CYP2C19ALOX15 | |
| SCHEMBL2805443 | 0.86 | — | — | |
| SCHEMBL185263 | 0.86 | — | — | |
| SCHEMBL16868374 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL3032015 | 0.84 | NSD2 (0.39) | NSD2GRM4CYP1A2CYP2C19ALOX15 | |
| SCHEMBL7114208 | 0.78 | NPSR1 (0.37) | CYP2C19CYP2C9LMNA | |
| SCHEMBL3658341 | 0.76 | — | — | |
| SCHEMBL27202100 | 0.74 | — | — | |
| Cycloleucine SCHEMBL21462057 | 0.73 | NSD2 (0.50) | NSD2GRM4CYP1A2CYP2C19ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028611-A | Method for synthesizing 4-aminotetrahydro-2-pyran-4-carboxylic acid | 富乐马鸿凯（大连）医药有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113912418-A | High-strength porous shale brick sintered by modified straw and preparation method thereof | 安徽创新秸秆利用有限公司 | 2022-01-11 | — | — | CN | claimed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | UCB HOLDINGS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4218790-B1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-06-12 | — | — | US | disclosed |
| US-6630594-B2 | Spiro-pyran compounds; use as pesticides and herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20020161034-A1 | Methods of making substituted phenylketoenols | HAGEMANN HERMANN (DE) | 2002-10-31 | — | — | US | disclosed |
| US-20020072617-A1 | Novel substituted phenylketoenols | HAGEMANN HERMANN (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6391912-B1 | PESTICIDES, HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6288102-B1 | Substituted phenylketoenols and their use as pesticides and herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| CN-1240449-A | Substituted phenylketoenols and their use as pesticides and herbicides | BAYER AG (DE) | 2000-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072617-A1 | Novel substituted phenylketoenols | CYP2E1, CYP4X1, CYP1A1 | NSD2 4230/4885GRM4 2024/4885CYP1A2 33/4885 |
| US-20020161034-A1 | Methods of making substituted phenylketoenols | CYP2E1, CYP1A1, KMO | NSD2 4171/4885GRM4 2659/4885CYP1A2 25/4885 |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | NSD2 3444/4885GRM4 3096/4885CYP1A2 4884/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | NSD2 1657/4885GRM4 2813/4885CYP1A2 4881/4885 |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | ASGR1, GPR119, LDLR | NSD2 3258/4885GRM4 1631/4885CYP1A2 2703/4885 |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | C5, C1R, SRPRB | NSD2 2374/4885GRM4 2079/4885CYP1A2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.